Endocrinology, Vol 104, 1270-1273, Copyright © 1979 by Endocrine Society

ARTICLES

Somatostatin analogs inhibit somatostatin release

E Ipp, J Rivier, RE Dobbs, M Brown, W Vale and RH Unger

To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp8-D-Cys14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn5-[D-Trp8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn5-[D-Trp8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn5-[D- Trp8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.

This article has been cited by other articles:

				Y. Patel, M Amherdt, and L Orci Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets Science, September 17, 1982; 217(4565): 1155 - 1156. [Abstract] [PDF]

				M. Lumpkin, A Gegro-Vilar, and S. McCann Paradoxical elevation of growth hormone by intraventricular somatostatin: possible ultrashort-loop feedback Science, March 6, 1981; 211(4486): 1072 - 1074. [Abstract] [PDF]